Keratoacanthoma Market Research Report-Forecast to 2030

Keratoacanthoma Market Information,by Treatment (Medication, Surgery – Cryosurgery and Mohs’ Microscopic Surgery, Intralesional Injection, Radiation Treatment & X-ray Therapy, and Others), by end user (Hospitals,Medical Research Laboratoriesand Others) and by Regions- Forecast to 2030

ID: MRFR/MED/1233-HCR | February 2023 | Region: Global | 90 Pages         

Keratoacanthoma Market Overview


The Keratoacanthoma Market is expected to reach USD 3,875.8 Million by 2030 at 7.3% CAGR during the forecast period 2022-2030. Keratoacanthoma (KA) is a skin ailment in which a small dome or crater forms as a result of a low-grade, slow-growing skin cancer tumor. Despite its look and other similarities to Squamous Cell Carcinoma  (SCC), it is benign in origin. KA starts in the skin's hair follicles and only spreads to other cells in a very small percentage of cases. This disorder is most common in persons over the age of 60, although it can also arise in those who are exposed to the sun, come into contact with chemical carcinogens, or become infected.


This disorder, also known as solar keratosis or senile keratosis, is characterized by a patch or small spot on the skin that grows slowly and causes no symptoms. These patches take years to develop, and they commonly emerge in adults over 60. Keratoacanthoma is more common in older persons who have pale eyes, fair skin, and red or blonde hair and who burn easily and don't tan well. Keratoacanthoma can progress to an aggressive type of skin cancer in some cases. Growth, discomfort/tenderness, and chronic ulceration or bleeding are all signs of squamous cell carcinoma progression. According to a study report published in the British Journal of Dermatology by J. Welzel, more than half of the light-skinned population would develop Keratoacanthoma during their lifetime. Keratoacanthoma is the third most prevalent reason for people to visit a dermatologist in the United States. Furthermore, according to the Skin Cancer Foundation, squamous cell carcinoma kills over 15,000 Americans each year..


COVID -19 Analysis


The COVID-19 pandemic had a significant influence on trade and industry. Manufacturers are rearranging their sales channels and developing new items to recover from the existing situation. The duration of the pandemic's propagation is still a key factor in assessing the pandemic's overall impact. However, the global Keratoacanthoma Market Growth is expected to stabilize after 2021. As the outbreak had little effect on the liquor industry, it has no bearing on the Global market analysis. Keratoacanthoma (KA) is a skin disorder in which a small dome or crater forms as a result of a low-grade, slow-growing malignant tumor. Despite its look and other similarities to squamous cell carcinoma, Keratoacanthoma (KA) begins in the skin's hair follicles and only rarely spreads to other cells. As a result, during the forecast term, the market trends will remain constant and will change the Keratoacanthoma Market Outlook.


Keratoacanthoma Market Dynamics


Drivers


The market has grown due to an aging population and those who do not avoid direct sun exposure for long periods. Rising exposure to chemical carcinogens, or cancer-causing substances, as well as an increase in chain smokers and infection with certain strains of a wart virus, such as the human papillomavirus, are among the key drivers driving the Keratoacanthoma Market Growth. As a result, as the population ages, the market is predicted to grow. The bulk of it is detected, staged, and treated during surgery. The market Value may be fueled by advancements in cancer treatments and therapies.


Restraints


The primary aspect, among others, that will block Market expansion and will further challenge the market share in the forecast future is growing treatment prices. keratoacanthoma market is expected to be stifled by the treatment's undesirable effects and the government's rigorous rules. Because Keratoacanthoma is such a common type of cancer, there are few studies on its risk factors and causes, which can be a disadvantage for the market when it comes to diagnosis. On the other side, the high cost of Keratoacanthoma therapy is expected to hinder the Keratoacanthoma Market Size. According to the American Cancer Society, radiation can destroy bone marrow, resulting in low blood levels. As a result, detrimental effects are expected to hinder the market share.


The keratoacanthoma market is attributed to the growing geriatric population. In the forecasted period, rising technological advancements and modernization in paracetamol production, rising research and development activities in the healthcare sector, and rising emerging markets with an increasing geriatric population base will all create new opportunities for the keratoacanthoma market. Keratoacanthoma therapy is also being tested in clinical trials. As a result, in the market outlook, technology has shown to be quite important.


Keratoacanthoma Market Segment Overview


Based on the treatment, the global Market has been segmented as follows:



  • Medication

  • Surgery (Cryosurgery and Mohs’ Microscopic Surgery)

  • Intralesional Injection

  • Radiation Treatment

  • X-ray therapy

  • Others


Based on the end-user, the global Market has been segmented as follows:



  • Hospitals

  • Medical Research Laboratories

  • Others


Keratoacanthoma Market Regional Classification


Keratoacanthoma has its largest market in North America. The Keratoacanthoma market in North America is predicted to expand rapidly and reach its peak by the end of the forecasted period. The market in this region is the greatest due to a growing senior population, increased interaction with chemical carcinogens, or cancer-causing chemicals, and an increase in chain smokers. Keratoacanthoma affects more than 40 million Americans each year, according to the American Academy of Dermatology Association.


Furthermore, Keratoacanthoma is inclined to develop in roughly 60% of Americans over the age of 60, with at least one Keratoacanthoma symptom. Furthermore, the presence of well-established healthcare infrastructure and increased healthcare spending is also fueling the growth of the entire regional market to a great extent. The second-largest market for the Keratoacanthoma market is Europe, which is predicted to rise fast due to increased technological advancements as well as macroeconomic and regulating variables in the region. Due to increased interaction with chemical carcinogens, or cancer-causing substances, the Asia Pacific area is predicted to be the fastest expanding region in the Keratoacanthoma market.


Americas




  • North America

    • US

    • Canada



  • Latin America


Europe




  • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK



  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea



  • Rest of Asia-Pacific


The Middle East & Africa



  • Middle East

  • Africa


Keratoacanthoma Market Competitive Landscape


The competitive landscape for the Keratoacanthoma market is broken down by competitors. The details which are included in the purview of analysis are Company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The information presented above is only about the companies' emphasis on the market. The major key players of the market are as follows:



  • Cipla Ltd.

  • GE Healthcare

  • Glenmark Pharmaceuticals Ltd.

  • Hospira

  • Pfizer

  • Philips Healthcare

  • Ranbaxy Laboratories Ltd.

  • Bausch Health Companies Inc.

  • Sanofi

  • Siemens Healthcare

  • Others


Recent Developments


Pfizer Inc. has completed the spin-off of its Upjohn business and the merger of it with Mylan N.V. to become Viatris Inc.


Bausch Health Companies Inc. has agreed to purchase an option to buy Allegro Ophthalmics' entire ophthalmology business.


Report Overview


The Keratoacanthoma market report includes information on recent market developments, drivers, restraints, technological advancements, value chain optimization, market share, the impact of major key market players, changes in market regulations, strategic market growth analysis, market size, category market growths, and dominance, product approvals, product launches, and geographic expansions. The research looks at the numerous elements that influence market dynamics, as well as key and connected industries, and helps firms comprehend different client propositions. The study provides historical and future revenue for market segments and sub-segments in four major continents and countries: the Americas, Europe, Asia-Pacific, the Middle East, and Africa. The study also includes a country-level analysis of the market for segments by therapy, end-user, and geography, as well as other sub-segments.


Intended Audience



  • Pharmaceutical Companies

  • Suppliers for medical and surgical types of equipment

  • Research and Development (R&D) Companies

  • Hospitals and Clinics

  • Diagnostic Laboratories & Centers

  • Medical Research Laboratories

  • Others



Report Scope:

Report Attribute/Metric Details
  Market Size   3,875.8 Million
  CAGR   7.3%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Treatment, End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cipla Ltd., GE Healthcare, Glenmark Pharmaceuticals Ltd., Hospira, Pfizer, Philips Healthcare, Ranbaxy Laboratories Ltd., Sanofi, Siemens Healthcare
  Key Market Opportunities   New product developments
  Key Market Drivers

  • Growing ageing population
  • People notavoiding direct sun exposure for prolonged hours


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Major end users of the keratoacanthoma market include medical research laboratories, hospitals, and others.

    North America will dominate the keratoacanthoma market.

    The different treatments for keratoacanthoma include x-ray therapy, radiation treatment, intralesional injection, Moh’s microscopic surgery, cryosurgery, and medication.

    Key players profiled in the keratoacanthoma market include Siemens Healthcare, Sanofi, Ranbaxy Laboratories Ltd., Philips Healthcare, Pfizer, Hospira, Glenmark Pharmaceuticals Ltd., GE Healthcare, and Cipla Ltd.

    Key players have adopted several strategies to stay ahead in the completion such as collaborations, joint ventures, mergers, acquisitions, and strategic alliances.